aifollow.news
Back IT之家 科技新闻
IT之家 科技新闻· · Original publication time AI score53

Isomorphic Labs completes $5 billion Series C funding roundMachine translation

Isomorphic Labs 完成 50 亿美元 C 轮融资

AI-assisted summary

Alphabet's AI drug discovery company Isomorphic Labs announced a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital. It plans to use the funding to advance foundational simulation models, expand its internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.

Article · AI translation

IT Home reported on November 17 that Isomorphic Labs, an Alphabet subsidiary developing drugs with AI and led by Nobel laureate Demis Hassabis, announced today local time that it had completed a Series C funding round totaling $5 billion (IT Home note: approximately 33.396 billion yuan at the current exchange rate).

The round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z (Andreessen Horowitz) joining. Alphabet continued to invest substantial funds, while existing investors including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participated.

Isomorphic Labs plans to use the funds to continue developing foundational simulation models, expand the scale of its internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.

Found an error? Send a correction